

New from the Global Health Security Consortium

## ONE SHOT: MAKING PREVENTABLE DISEASE HISTORY

- New global campaign to make preventable disease history launched today by the Global Health Security Consortium
- One Shot roadmap sets out how this can be done – building on the response to Covid-19 and capitalising on the potential of next-generation vaccines and injectable therapeutics
- Governments, industry and global health organisations urged to come together to realise this vision as leaders and representatives prepare to attend the World Health Summit in Berlin

One Shot: Making Preventable Disease History is the goal of a new campaign launched today by the Global Health Security Consortium (GHSC) – a partnership between the Tony Blair Institute for Global Change, the Ellison Institute for Transformative Medicine and the University of Oxford, alongside a roadmap setting out how this can be achieved.

The response to Covid-19 saw huge advancements in the development of life-saving vaccines. One Shot seeks to build on these by creating a roadmap to transform global health infrastructure – driving the shift towards preventative health and bolstering preparedness for future pandemics. This means harnessing the potential and demand for next-generation vaccines to tackle diseases such as dengue, human papillomavirus, malaria,

respiratory syncytial virus and tuberculosis, as well as novel injectable prophylactics for conditions including heart disease and HIV.

The potential rewards are huge in terms of lives saved and life expectancy prolonged. At least 10 million deaths a year are attributable to diseases with existing or imminent adult vaccines and preventable injectable therapies. This includes non-communicable diseases (NCDs) such as cardiovascular and respiratory diseases, cancer and diabetes: collectively responsible for over 70 per cent of deaths worldwide.

**Tony Blair, Executive Chairman of the Tony Blair Institute for Global Change (TBI), said:**

“One Shot aims to bring the next generation of life-saving vaccines and treatments to everyone, everywhere but that can only happen if we put in place the global health structure to achieve it.

“The loss of 10 million lives every year from preventable diseases is a cost to humanity that is just unacceptable when we have within our grasp the means to prevent it. We have got one shot to get this right.

“Bringing together governments, industry and global health organisations to deliver our One Shot vision will save millions of lives, billions of dollars and help to address vast health inequalities, creating more prosperous, healthier and more resilient societies.”

**Dr David Agus, Founding Director and CEO of the Ellison Institute for Transformative Medicine, said:**

“One Shot is a transformative moment for human history. Covid-19 showed us that the rollout of adult vaccination on a global scale is possible and it hammered home that we’re not all safe until everyone is safe.

“One Shot will build on this momentum to deliver huge social and economic benefits. And it will unlock investment in digital and manufacturing infrastructure that will revolutionise health-care delivery around the world.”

**Sir John Bell, Regis Professor University of Oxford, said:**

“The aim of One Shot is simple – it’s a public-health solution for the world. Our goal is to ensure all adults, everywhere, have access to the next generation of vaccines and preventative injectables.

“The next five years will see huge possibility for medical advances in some of the poorest countries, so the international community must come together for this common purpose.”

**Dr Richard Hatchett, CEO of CEPI, the Coalition for Epidemic Preparedness Innovations, said:**

“CEPI is a strong supporter of the One Shot initiative. It will bring immediate benefits in terms of disease reduction, increase access to and demand for vaccines, and contribute to the sustainability of new

manufacturing facilities. Strengthening the vaccine delivery infrastructure for high-risk populations in this way will pay huge dividends in future public-health emergencies. Establishing such a capability on the foundations laid by Covid-19 vaccine delivery programs could be one of the most important and beneficial legacies of the pandemic.”

**Dr Trevor Mundel, Head of the Global Health Programme, Bill & Melinda Gates Foundation, said:**

“Increasing access to existing and novel vaccines for people in low- and middle-income countries will save millions of lives and help create and sustain the infrastructure needed to respond to future pandemics. We need collaboration across the public, private, and nonprofit sectors to deliver on the vision to make preventable disease history. The Gates Foundation fully supports the aims of the One Shot Campaign and its partners in these shared goals.”

**Dr Ebere Okereke, Senior Health Advisor at TBI, said:**

“Health is at the heart of development and economic progression. If you haven’t got good health, everything else falls apart. Despite the success of Covid-19 vaccine development, inequality in access remains a major issue.

“Low- and middle-income countries do not want to continue to rely on handouts; instead, they are determined to build capacity and expertise and to be part of global self-sufficiency. One Shot recognises the importance of equity in implementing these opportunities.”

**Dr Amadou Sall, General Administrator,  
Institut Pasteur de Dakar:**

“I strongly believe that the GHSC’s new One Shot initiative can have a major impact on making preventable disease history.

“Now is the time for governments, industry and international health organisations to come together to increase vaccine research and development, expand regional manufacturing networks and increase vaccine access across the Global South.

“Senegal’s Institute Pasteur Dakar is at the forefront of this agenda. Our MADIBA project, delivered in partnership with the government of Senegal, CEPI and several financial institutions and technical partners, will enable manufacture of up to 300 million doses of multi-client vaccines per year.”

**Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), said:**

“As the global pharmaceutical industry that rapidly developed and delivered billions of novel Covid-19 vaccines which contributed to saving the lives of millions of people around the world, we recognise the importance of working with governments and global health organisations during the pandemic to improve access to vaccination, for people, wherever they live.

“We look forward to being actively engaged with the One Shot campaign to ensure that our collective efforts deliver on this important global agenda.

“Global collaborative initiatives such as the One Shot campaign are critical to informing and focusing all stakeholders, including governments, on the real challenges of meeting vaccine inequity and the need for a re-energised focus on the power of vaccines more generally. Life-course immunisation can contribute to healthier, more productive and longer lives, which enhances the sustainability of health-care systems.

“Inequity in vaccine access remains a major risk to global health. In addition to being a steadfast innovator of vaccines that address unmet medical needs, and our years as an active partner to Gavi, the Vaccine Alliance, industry is fully committed to engage in finding sustainable solutions to vaccine equity and access. As outlined in our recent proposal for future global pandemic equity (the [Berlin Declaration](#)), with all partners working together, we can tackle the challenge of securing access to pandemic vaccines, diagnostics and therapeutics for lower-income countries.”

## A NEW VISION FOR GLOBAL HEALTH

As part of the campaign launch, GHSC is publishing the first two papers in a series that will provide the roadmap and recommendations to deliver the One Shot vision.

The first, One Shot to Prevent Disease and Prepare for Future Pandemics, sets out the overall aims and framework, from supporting existing research and development initiatives, to expanding and diversifying manufacturing networks and continuing to invest in and implement digital infrastructure. The second paper assesses the current pipeline for innovative vaccines and injectable therapeutics, which have the potential to revolutionise preventative health and includes recommendations to capitalise on these new technologies.

The GHSC expresses its full support for the leading role of the World Health Organisation in ensuring equitable access to vaccines, and aligns with the Immunization Agenda 2030. The Consortium calls on the international community to provide the necessary funding and assistance so that this new generation of vaccines and injectables can be made available to all who need them, helping save millions of lives and improving the economic prospects of all nations damaged at present by preventable disease.

India, who will be taking over Presidency of the G20 in 2023 having delivered more than 2 billion Covid vaccinations, has expressed early support for the campaign stating that it aligns with their domestic and international health objectives.

## ONE SHOT, SIX GOALS

A vision for global health infrastructure built on vaccinations and injectables for adults, which complements the existing infrastructure for children, will:

1. **Improve equity of access to vaccines and medicines** around the world
2. **Re-orientate care towards prevention** and away from treatment of sickness
3. **Strengthen health-systems functions** such as supply chains, service delivery and workforce
4. **Create standing infrastructure and human capital to prevent and respond to outbreaks and pandemics**
5. **Grow economies and investment** in the life sciences and in the health-care sector
6. **Accelerate the establishment of a digital health infrastructure** that will have lasting utility beyond disease prevention